Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Herpes simplex virus infection.

Richard J Whitley1

  • 1Department of Pediatrics, University of Alabama at Birmingham, USA. rwhitley@peds.uab.edu

Seminars in Pediatric Infectious Diseases
|July 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oseltamivir drug-disease modelling in infants with influenza virus infection.

British journal of clinical pharmacology·2026
Same author

Temperature-Dependent Viral Pathogenicity: Implications for Attenuation of Viral Vaccines.

Viruses·2026
Same author

Introduction and Update: Advances in Influenza Therapeutics.

The Journal of infectious diseases·2025
Same author

Ganciclovir Dosing in Premature Infants Receiving Treatment for Congenital Cytomegalovirus Infection: Results of a Prospective Pharmacokinetic Study.

The Journal of infectious diseases·2025
Same author

Valacyclovir Pharmacokinetics in Infants With Neonatal Herpes Simplex Virus Disease.

The Pediatric infectious disease journal·2025
Same author

A randomized, placebo-controlled, dose-escalation phase I/II multicenter trial of low-dose cidofovir for BK polyomavirus nephropathy.

Transplant infectious disease : an official journal of the Transplantation Society·2024
Same journal

Editorial.

Seminars in pediatric infectious diseases·2020
Same journal

Viral pharyngitis.

Seminars in pediatric infectious diseases·2020
Same journal

The epidemiology of respiratory infections in children.

Seminars in pediatric infectious diseases·2020
Same journal

Antiviral agents in the critically ill child.

Seminars in pediatric infectious diseases·2020
Same journal

Serious and lethal respiratory tract infections of viral etiology in children.

Seminars in pediatric infectious diseases·2020
Same journal

Subject index.

Seminars in pediatric infectious diseases·2020
See all related articles

Herpes simplex virus (HSV) infections are common, causing mild to severe disease. Antiviral drugs like acyclovir, valaciclovir, and famciclovir effectively manage HSV by inhibiting replication and reducing viral shedding.

Area of Science:

  • Virology
  • Infectious Diseases
  • Dermatology

Background:

  • Herpes simplex virus (HSV) is a prevalent human pathogen, with HSV-1 typically causing orolabial disease and HSV-2 associated with genital and neonatal infections.
  • While often self-limiting, HSV can lead to severe, life-threatening conditions like neonatal infections and central nervous system disease, particularly in immunocompromised individuals.
  • Genital HSV infections increase the risk of HIV acquisition and can cause debilitating recurrent episodes even in immunocompetent hosts.

Purpose of the Study:

  • To review the clinical significance of HSV infections.
  • To discuss the development and efficacy of antiviral therapies for HSV.
  • To highlight the long-term safety and limitations of current HSV treatment options.

Main Methods:

Related Experiment Videos

  • Literature review of HSV epidemiology, clinical manifestations, and treatment strategies.
  • Analysis of antiviral agents targeting HSV replication, including acyclovir, valaciclovir, and famciclovir.
  • Evaluation of the safety and effectiveness data for established and newer anti-HSV medications.

Main Results:

  • Acyclovir, valaciclovir, and famciclovir are effective in accelerating healing and reducing viral shedding in HSV infections.
  • Long-term safety data for acyclovir is well-established.
  • Valaciclovir and famciclovir, while effective, have shorter track records, and pediatric formulations are not widely available.

Conclusions:

  • Antiviral therapies have significantly improved the management of HSV infections, reducing morbidity and transmission risk.
  • Continued research into the long-term safety and development of pediatric formulations for newer agents is warranted.
  • HSV management requires consideration of disease severity, host immune status, and recurrence patterns.